Wegovy pill is the new form of the Wegovy injection, which is available as a once-daily oral tablet. Promotes fat loss and metabolic improvements, not just temporary reductions in water or muscle mass. It can help improve blood sugar, cholesterol, and blood pressure, even in people without diabetes.
Novo Nordisk has successfully trialled a daily pill version of Wegovy (oral semaglutide) specifically for weight loss in 25mg and 50mg doses. Clinical trials indicate that the oral tablet can help users lose an average of 16.6% of their body weight. The medication also demonstrated significant individual success, with over 34% of fully adhering participants achieving a weight loss of 20% or greater. These results are highly comparable to the efficacy of the established weekly injection.
How does Wegovy pill work?
Wegovy belongs to a class of medications called GLP-1 receptor agonists. Delivers the same weight-loss power as the popular weekly injection. These work by mimicking a natural hormone that:
- Reduces appetite and targets brain regions involved in appetite regulation.
- Slows stomach emptying, which affects how quickly food passes through your system.
- Helps you feel full longer, leading to a decrease in overall calorie intake.
Wegovy pill contains semaglutide with an absorption enhancer (SNAC) that protects it from stomach acid. This allows the medication to be absorbed effectively when taken on an empty stomach with water, and to wait at least 30 minutes before eating or drinking anything else.
Clinical Efficacy: How Effective is the Oral Pill?
Recent clinical trials (OASIS 1 and OASIS 4) show that the new higher-dose oral semaglutide tablets (25 mg and 50 mg) are just as effective as the traditional 2.4 mg injection, delivering an average weight loss of 14% to 17% over 64 to 68 weeks.
- Proven Efficacy: Achieves up to 17% weight loss in patients with full treatment adherence, matching the established clinical outcomes of weekly injections.
- Consistent Results: Maintains a reliable 14% average weight loss under real-world conditions, even when accounting for occasionally missed doses.
- Significant Milestones: Over a third (34%) of patients who consistently maintained the 25 mg dose successfully lost at least 20% of their starting body weight.
- Comprehensive Health Benefits: Promotes enhanced physical mobility and assists in lowering key cardiovascular risk factors.
- Tolerability: Side effects are generally mild to moderate, predominantly gastrointestinal, and mirror the safety profile expected with injectable treatments
Prescribing Protocol: The Dose Escalation Schedule
| Phase | Timing | Daily Dosage |
|---|---|---|
| Month 1 | Days 1–30 | 1.5 mg (Starting Dose) |
| Month 2 | Days 31–60 | 4 mg |
| Month 3 | Days 61–90 | 9 mg |
| Month 4+ | Day 91 onwards | 25 mg (Maintenance) |
Wegovy Tablets Eligibility:
Wegovy tablets must be prescribed by a licensed healthcare professional following a clinical assessment. This includes reviewing your BMI, medical history, and any existing conditions.
Who Can Be Eligible?
You may be considered for Wegovy if you are an adult and meet one of these criteria:
- BMI ≥30 (Obesity)
- BMI ≥27 (Overweight) plus at least one weight-related health issue, such as high blood pressure, high cholesterol, or Type 2 diabete
- Disclaimer: Any adjustments to the Wegovy® dosing schedule should be determined by a healthcare professional based on individual tolerance and medical history.
Reviews
There are no reviews yet